314 research outputs found
Estudo das reflexões de ordens superiores em cristais monocromadores de nêutrons
Orientador: Marcello Damy de Souza SantosTese (doutorado) - Universidade Estadual de CampinasResumo: Não informadoAbstract: Not informed.DoutoradoFísicaDoutor em Ciência
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?
Background: The immune response in melanoma patients is locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk, nonbrisk, and absent. Several studies have shown that a greater presence of TILs, especially brisk, in primary melanoma is associated with a better prognosis and higher survival rate. Patients and Methods: We investigated by enzyme-linked immunosorbent assay (ELISA) the correlation between PD-1 levels in plasma and the presence/absence of TILs in 28 patients with metastatic melanoma. Results: Low plasma PD-1 levels were correlated with brisk TILs in primary melanoma, whereas intermediate values correlated with the nonbrisk TILs, and high PD-1 levels with absent TILs. Although the low number of samples did not allow us to obtain a statistically significant correlation between the plasma PD-1 levels and the patients' overall survival depending on the absence/presence of TILs, the median survival of patients having brisk type TILs was 5 months higher than that of patients with absent and nonbrisk TILs. Conclusions: This work highlights the ability of measuring the plasma PD-1 levels in order to predict the prognosis of patients with untreated metastatic melanoma without a BRAF mutation at the time of diagnosis
Isolated Metachronous Splenic Metastasis from Colon Cancer: Possible Explanations for This Rare Entity
The incidence of splenic metastases secondary to colorectal cancer is very low; these lesions have been more frequently reported as secondary to breast, lung, and ovarian cancer. Splenic metastases are particularly common in melanoma; their incidence has been reported as being as high as 34% at autopsy [1]. Most cases of secondary splenic metastases have been described in patients with tumors of the left colon while only few cases being reported as originating from right colon tumors (Table 1). The finding of a splenic mass in the absence of a history of malignancy suggests a primary lesion (lymphoma, hematoma, etc.), while a history of oncological disease raises the possibility of a secondary lesion [2]
Geologia da margem ocidental da bacia do Parnaíba (Estado do Pará)
The Parnaíba sedimentary basin western margin geology in the State of Pará, Brazil, indicates that the present basin margin is of a tectonic origin and not its original depositional limit. The Paleozoic section bearing fine sediments are strongly faulted and is covered by an extensive Cenozoic sedimentation probably the last period of tectonic reactivation. To the north, parallel to the Tocantins river, a thick Quaternary sedimentation covers all the preceding formations reaching colossal thicknesses at the mouth of the Amazon river.A geologia da margem oeste da bacia sedimentar do Parnaíba no Estado do Pará, Brasil, indica que a presente borda da bacia é de origem tectônica e não representa, portanto, o seu limite original de deposição. A seção paleozóica da bacia, constituída de sedimentos finos, é fortemente falhada e recoberta por uma sedimentação cenozóica extensiva, que provavelmente representa o último período de reativação tectônica. Para o norte, paralelamente ao rio Tocantins, a espessa sedimentação quaternária recobre todas as formações precedentes chegando a colossais espessuras na foz do rio Amazonas
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma
Background: Neutropenia and its complications
represent one of the principal dose-limiting toxicity issues in
chemotherapeutic regimens for soft tissue sarcoma.
Prophylactic granulocyte colony-stimulating factor (G-CSF)
reduces the risk of febrile neutropenia (FN). The correct
timing of G-CSF administration should be considered in order
to optimize the prophylactic treatment. Patients and Methods:
Patients (≥18 years old) affected by soft tissue sarcoma and
treated with epirubicin and ifosfamide, underwent prophylactic
treatment with G-CSF (lenograstim at 263 μg) from day 5 to
day 9. The proportion of patients experiencing FN and G4
neutropenia was considered. Results: A total of 36 patients
receiving three cycles of chemotherapy with epirubicin plus
ifosfamide were treated. None developed FN; G4 neutropenia
was reported in 17% of patients. No treatment delay or dose
reduction was required, no antibiotic therapy was
administered and no hospitalization occurred. Conclusion:
Five-day lenograstim treatment is efficient as prophylaxis of
FN for soft tissue sarcoma chemotherapy regimens and allows
maintenance of chemotherapy dose intensity
Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients
Abstract
OBJECTIVES:
To assess the level of pain intensity at which patients feel the impetus to ask for a breakthrough cancer pain (BTcP) medication, and level of pain intensity at which patients consider they have achieved acceptable pain control after receiving a BTcP medication.
METHODS:
A consecutive sample of patients who were receiving oral morphine equivalents equal to or more than 60\u2009mg daily, and were prescribed rapid onset opioids for the management of episodes of BTcP, were included in the study. Focused educational activities regarding BTcP and numerical scales were established during hospital admission. At discharge patients were interviewed to find out what was the pain intensity level which gave the impetus to take the BTcP medication, what was the pain intensity for acceptable pain control after a BTcP medication had been given, and which factors prevented the patient calling for BTcP medication. A brief COPE (coping orientation to problems experienced) questionnaire was also administered.
RESULTS:
Fifty-two patients were recruited for this study. The meaningful pain intensity for asking for a BTcP medication was 7.1; 77% of patients had a pain intensity of 7-8 on a numerical scale of 0-10. The meaningful pain intensity for adequate analgesia after a BTcP medication was 3.5. Similarly, 77% of patients had a pain intensity of 3-4. There was no relationship with the variables examined. Concerns by patients about the use of BTcP medications were minimal.
CONCLUSION:
The meaningful BTcP intensity and pain intensity expected after BTcP medication can be useful in selecting patients in studies of BTcP. The principal limitation of this study was the specific setting of an acute unit with specific features and the relatively low number of patients. This observation should be followed up by further surveys with a larger number of patients and different settings
Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study.
Objective: According to experimental findings, oxycodone (OX) could have
some advantages over morphine (MO) in clinical models of visceral pain. It
was hypothesized that OX could have some advantages over MO in terms of
efficacy and dose escalation in pancreatic cancer pain. Methods: Sixty
patients with pancreatic cancer with a pain intensity rating of 4/10 who
required opioids were included in the study. Patients were randomized to
receive 30mg/d of sustained release oral MO or sustained release oral OX
(20mg/d). Opioid doses were increased according to the clinical needs. Daily
doses of opioids, pain and symptom intensity were recorded at admission (T0)
and at weekly intervals for the subsequent 4 weeks (T1, T2, T3, and T4),
with an extension at 8 weeks (T8). Opioid escalation index (OEI) as
percentage (OEI %) and in mg (OEI mg) was calculated. Results: Nineteen and
20 patients in groups OX and MO, respectively, were followed for the entire
period of study (T4). No differences between groups were found in age
(P=0.400), Karnofsky (P=0.667), or escalation indexes at T4 and T8 (OEImg,
P=0.945 and OEI %, P=0.295). No statistical differences in pain and symptoms
intensity between the groups were observed. Conclusion: OX and MO provided
similar analgesia and adverse effects with similar escalating doses in
patients with pancreatic cancer pain, resembling observations reported in
the general cancer pain population. The experimental hypothesis that OX
would be superior to MO in the clinical model of pancreatic cancer pain was
not confirmed. © 2010 by Lippincott Williams & Wilkins
Surgical Treatment of Extravasation Injuries
The authors present their experience of treating anti-cancer drug extravasation by means of a composite surgical technique that consists of infiltration with physiological solution and hyaluronidase and subsequent manual aspiration of solutes alternated with profuse irrigation of the infiltrated area. In the immediate post-op we carry out a medical therapy that consists of calciparine and topic antibiotic and/or steroid creams. Since the year 2000 this technique has been used on 25 patients. We have had neither complications nor scars. Copyright 2005 Wiley-Liss, IncSurgical treatment of extravasation injuries.
Napoli P, Corradino B, Badalamenti G, Tripoli M, Vieni S, Furfaro MF, Cordova A, Moschella F.
Source
Chirurgia Plastica e Ricostruttiva, Dipartimento di Discipline Chirurgiche ed Oncologiche, Università degli Studi di Palermo, Italy. [email protected]
Abstract
The authors present their experience of treating anti-cancer drug extravasation by means of a composite surgical technique that consists of infiltration with physiological solution and hyaluronidase and subsequent manual aspiration of solutes alternated with profuse irrigation of the infiltrated area. In the immediate post-op we carry out a medical therapy that consists of calciparine and topic antibiotic and/or steroid creams. Since the year 2000 this technique has been used on 25 patients. We have had neither complications nor scars
Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis.
Although platinum-based combinations are considered the best option of care for patients
with advanced nonsmall cell lung cancer (NSCLC), single-agent therapy is the preferred treatment for older
patients. Since the late 1990s, various combinations of third-generation agents (gemcitabine [G], vinorel-
bine, docetaxel, and paclitaxel) have been tested, yielding contradictory results. The authors of this report
performed a literature-based meta-analysis to assess the efficacy and tolerability of G-based doublets
compared with single-agent chemotherapy for elderly patients with NSCLC.
METHODS: Data from all published, randomized, phase 3 trials that compared a G-based doublet with a third-generation single agent in elderly patients were collected from electronic databases (Medline and the Cochrane Central Register of Controlled Trials), relevant reference lists, and abstract books. Pooled odds ratios (ORs) were calculated for the 1-year survival rate, the overall response rate (ORR), and grade 3 and 4 toxicities. RESULTS: Four eligible trials (1436 patients) were selected from 442 studies that initially were identified. A significant difference in ORR favoring G-based doublets over single agents was observed (OR, 0.65; 95% confidence interval [95% CI], 0.51-0.82 [P<.001]), whereas the trend toward an improved 1-year survival rate was not significant (OR, 0.78; 95% CI, 0.57-1.06 [P¼.169]). Grade 3 and 4 toxicities did not differ significantly except for thrombocytopenia (OR, 1.76; 95% CI, 1.12-2.76 [P¼.014]).
CONCLUSIONS: G-based doublets appeared to be effective and feasible compared with single agents in the treatment of elderly patients with advanced NSCLC who were not suitable for full-dose, platinum-based chemotherapy. Further prospective, elderly specific, phase 3 trials will be necessary
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
Background: The effects of the bisphosphonate derivative zoledronic acid (ZA) on the
> circulating levels of matrix metalloproteinase-2 (MMP-2), matrix metallo-proteinases-9
> (MMP-9), cathepsin B (Cath B) and urokinase-type plasminogen activator (uPA) in
> patients with bone metastasis (BMTS) and the possible correlation with the symptomatic
> response induced by this drug in these patients were evaluated. Patients and Methods:
> Proteinase levels were determined by enzyme-linked immunosorbent assay (ELISA) in the
> plasma of 30 patients with painful bone metastases from breast or prostate cancer
> undergoing multiple treatment with ZA (4 mg i.v., every 4 weeks). Healthy subjects
> (HS) of both genders (12 female and 30 male) served as the control group. The
> symptomatic response to ZA was assessed by the visual analog scale score (VAS).
> Results: The median MMP-2 and MMP-9 pretreatment levels were more elevated in BMTS as
> compared to HS (p¡Ü0.0001). Conversely, uPA levels were lower in BMTS p=0.0033; no
> significant difference was observed for Cath B. ZA administration was associated with
> a symptomatic response (VAS score¡Ü4) in 25/30 patients (83.3%) (p<0.0001). This
> phenomenon paralleled a decrease of Cath B and MMP-2 plasma concentrations from
> baseline values on week 12 (p=0.05). A similar trend, although not statistically
> significant, was also noted for MMP-9 and uPA. However, no direct relationship was
> observed between the analgesic effect induced by ZA and changes in the circulating
> levels of these enzymes. Conclusion: These data show that ZA administration may
> provide relief from bone pain in patients with diffuse skeletal metastases and confirm
> a possible implication of cysteine proteinases and matrix metalloproteinases in bone
> metastasis formation, but not in the pathogenesis of metastatic bone pain
- …